Investor Presentation: July 2022

OTCQB: CYTR

CORPORATE OVERVIEW July 2022

CytRx Safe Harbor Statement

THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS "INTENDS," "MAY," "WILL," "PLANS," "EXPECTS," "ANTICIPATES," "PROJECTS," "PREDICTS," ESTIMATES," "AIMS," "BELIEVES," "HOPES," "POTENTIAL" OR SIMILAR WORDS. FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF MANAGEMENT AS WELL AS

CERTAIN ASSUMPTIONS MADE BY AND INFORMATION CURRENTLY AVAIALABLE TO MANAGEMENT, ARE NOT GUARANTEES OF FUTURE PERFORMANCE, AND ARE SUBJECT TO VARIOUS KNOWN AND UNKNOWN RISKS AND

UNCERTAINTIES, MANY OF WHICH ARE BEYOND CYTRX'S CONTROL, AND CANNOT BE PREDICTED OR QUANTIFIED AND

CONSEQUENTLY, RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD- LOOKING STATEMENTS AS A RESULT OF VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE RISK FACTORS DISCUSSED IN THE ANNUAL AND QUARTERLY REPORTS THAT CYTRX FILES WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. STATEMENTS CONTAINED HEREIN ARE MADE AS OF THE DATE OF THIS PRESENTATION UNLESS STATED OTHERWISE, AND NEITHER THIS PRESENTATION, NOR ANY SALE OF SECURITIES, SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER SUCH DATE OR THAT INFORMATION WILL BE UPDATED OR REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE OR CHANGES OCCURRING AFTER THE DATE HEREOF. CYTRX RESERVES THE RIGHT TO UPDATE, AMEND OR SUPPLEMENT THE INFORMATION AT ANY TIME IN ITS ABSOLUTE DISCRETION (WITHOUT INCURRING ANY OBLIGATION TO DO SO). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE DOCUMENTS FREE OF CHARGE ON THE SEC'S WEB SITE AT WWW.SEC.GOV. CYTRX ASSUMES NO OBLIGATION TO PUBLICLY UPDATE OR REVISE ITS FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

2

Management and Board

Stephen Snowdy, PhD

CEO

• Recently joined CytRx
• PhD Neurobiology University of North Carolina
• 20 years of experience in medical executive management
• • Venture capital
  • Medical devices
  • Pharma
  • IPO
  • Public company management

Gilad Gordon, MD

R&D/Regulatory

Consultant

• Oncology development expert
• 30 years experience developing cancer treatments
• Directly responsible for 50 INDs, hundreds of clinical trials

John Caloz

CFO

• 30+ years of CFO experience in life sciences sector
• Occulogix, IRIS Int'l, Synarc, Phoenix Int'l
  Life Sciences

Board of Directors

• Lou Ignarro, PhD

Outgoing Chairman of BoD and Comp Committee. Nobel Prize for Medicine 1998 for discoveries of nitric oxide as signaling molecule, PhD Pharmacology, Professor Emeritus UCLA School of Medicine

• Jennifer Simpson, PhD

CEO of Panbela Therapeutics. Former

CEO of Delcath, Oncology Lead at

Imclone, Product Director Oncology

Marketing at Ortho Biotech,

• Joel Caldwell

Chair of Audit Committee. 30 years of experience in tax, finance, and auditing.

3

Investment Highlights

CytRx has developed elegant tumor targeting and
release molecules called LADR that are based on		CytRx is stage-diversified, with LADR-based drugs stretching
small molecular entities (no complex antibodies or		from registrational Phase 2 in pancreatic cancer to late pre-
nanoparticles) allowing for higher dosing and		clinical next-gen drugs
lower off-target tox

• First LADR drug Aldoxorubicin has been licensed to Immunity Bio for $343+ million in milestones and royalties, contingent on regulatory approvals and commercial milestones
• Next-genLADR-based drugs are nearing readiness for IND
• Small and virtual to minimize cash use
• Strong, broad, and global patent portfolio
• Potential short-term upside with licensed product Arimoclomol expected to go to FDA for NDA in 1Q2023 (licensed by KemPharm)

4

LADR=Linker Activated Drug Release

LADR-based drugs take advantage of circulating albumin as Trojan Horse:

• Major source of amino acids for tumors*
• Tumors use as carrier for metabolites, hormones, nutrients*
• Undergoes macropinocytosis*
• Accumulates in tumors due to EPR*
• Long half life*

LADR:

Ultra High Potency Drug

Payload

• Payloads are effective in the nanomolar range
• Similar to those used for approved ADCs (auristatins and maytansinoids)

Cleavable Linker

• Novel linker keeps the highly potent drug payload inactive until the conjugate reaches the tumor
• The linker is then cleaved when exposed to lower pH in tumor and intracellular environments

Targeting

• Ensures rapid and selective binding to circulating serum albumin
• Serum albumin transports the LADR™ drug to the tumor

* Kratz, F. Albumin as a drug carrier. J Cont Rel (2008) 132:171-183

5